Combination Therapy for EGFR-Mutated Lung Cancer

被引：13

作者：

Wu, Yi-Long ^{[1
]}

Zhou, Qing ^{[1
]}

机构：

[1] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangdong Acad Med Sci, Guangzhou, Peoples R China

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2023年 / 389卷 / 21期

关键词：

OSIMERTINIB;

D O I：

10.1056/NEJMe2311559

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Targeted therapy has improved prognoses for patients with advanced non-small-cell lung cancer (NSCLC) that has epidermal growth factor receptor (EGFR) mutations. The seminal trial that established precision medicine for EGFR-mutated NSCLC was the Iressa Pan-Asia Study (IPASS),(1) and a second trial, AURA3, showed that resistance mutations could be detected and then targeted with osimertinib.(2) FLAURA was an important third trial that moved osimertinib to the first line of treatment by showing delayed resistance and improved clinical outcomes; progression-free survival was 18.9 months, and overall survival was 38.6 months.(3,4) Osimertinib became the standard therapy for advanced NSCLC with EGFR-sensitive mutations. The story . . .

引用

页码：2005 / 2007

页数：3

共 50 条

[21] Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies [J].

Di Noia, V. ;

D'Aveni, A. ;

D'Argento, E. ;

Rossi, S. ;

Ghirardelli, P. ;

Bortolotti, L. . ;

Vavassori, V. ;

Bria, E. ;

Ceresoli, G. L. .

ESMO OPEN, 2021, 6 (06)

[22] Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma [J].

Aredo, J. ;

Wakelee, H. A. ;

Neal, J. ;

Padda, S. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S619-S619

[23] Achievement of pathological complete response with osimertinib for EGFR-mutated lung adenocarcinoma [J].

Fujita, Yasuhiro ;

Take, Nobuyuki ;

Shinohara, Shinji ;

Mori, Masataka ;

Kanayama, Masatoshi ;

Takenaka, Masaru ;

Kuroda, Koji ;

Shimajiri, Shohei ;

Tanaka, Fumihiro .

GENERAL THORACIC AND CARDIOVASCULAR SURGERY CASES, 2023, 2 (01)

[24] Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma [J].

Torasawa, Masahiro ;

Yoshida, Tatsuya ;

Shiraishi, Kouya ;

Yagishita, Shigehiro ;

Ono, Hanako ;

Uehara, Yuji ;

Miyakoshi, Jun ;

Tateishi, Akiko ;

Igawa, Yukiko Shimoda ;

Higashiyama, Ryoko Inaba ;

Mochizuki, Akifumi ;

Masuda, Ken ;

Matsumoto, Yuji ;

Shinno, Yuki ;

Okuma, Yusuke ;

Goto, Yasushi ;

Horinouchi, Hidehito ;

Hamamoto, Ryuji ;

Yamamoto, Noboru ;

Watanabe, Shun-ichi ;

Yatabe, Yasushi ;

Takahashi, Kazuhisa ;

Kohno, Takashi ;

Ohe, Yuichiro .

LUNG CANCER, 2025, 202

[25] Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report [J].

Singh, Aditi ;

Sridhar, Arthi ;

Poddar, Aastha ;

Dimou, Anastasios ;

Parikh, Kaushal ;

Shanshal, Mohamed ;

Schwecke, Anna ;

Moffett, Nicole ;

Patel, Manish R. ;

Mansfield, Aaron S. ;

Leventakos, Konstantinos .

JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (06)

[26] MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer [J].

Yan, D. ;

Huelse, J. ;

Parker, R. ;

Wang, X. ;

Frye, S. ;

Earp, H. S. ;

Deryckere, D. ;

Graham, D. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) :S1147-S1147

[27] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance [J].

Fu, Kai ;

Xie, Fachao ;

Wang, Fang ;

Fu, Liwu .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)

[28] Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer [J].

Chevallier, Mathieu ;

Tsantoulis, Petros ;

Addeo, Alfredo ;

Friedlaender, Alex .

CANCER GENOMICS & PROTEOMICS, 2020, 17 (05) :597-603

[29] Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib [J].

Kunimasa, Kei ;

Kamada, Risa ;

Oka, Toru ;

Oboshi, Makiko ;

Kimura, Madoka ;

Inoue, Takako ;

Tamiya, Motohiro ;

Nishikawa, Tatsuya ;

Yasui, Taku ;

Shioyama, Wataru ;

Nishino, Kazumi ;

Imamura, Fumio ;

Kumagai, Toru ;

Fujita, Masashi .

JACC: CARDIOONCOLOGY, 2020, 2 (01) :1-10

[30] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer [J].

Wang, Huaying ;

Lin, Lie ;

Liang, Chuqiao ;

Pang, Jiaohui ;

Yin, Jiani C. ;

Zhang, Junli ;

Shao, Yang ;

Sun, Chengming ;

Guo, Renhua .

JCO PRECISION ONCOLOGY, 2024, 8

← 1 2 3 4 5 →